Akari Therapeutics (NASDAQ:AKTX) Now Covered by Analysts at StockNews.com
StockNews.com initiated coverage on shares of Akari Therapeutics (NASDAQ:AKTX – Free Report) in a research note issued to investors on Sunday. The firm issued a sell rating on the biopharmaceutical company’s stock. Akari Therapeutics Trading Down 2.6 % NASDAQ:AKTX opened at $2.24 on Friday. The firm has a fifty day simple moving average of $2.81 […]
More Stories
Where Food Comes From Reports Financial Results for Third Quarter of 2024
Where Food Comes From, Inc. (NASDAQ:WFCF) has released its financial results for the third quarter of 2024 through a recent...
ING Groep NV Buys 240,749 Shares of The Estée Lauder Companies Inc. (NYSE:EL)
ING Groep NV increased its stake in shares of The Estée Lauder Companies Inc. (NYSE:EL – Free Report) by 393.7%...
ING Groep NV Trims Stock Holdings in Ecolab Inc. (NYSE:ECL)
ING Groep NV lessened its stake in shares of Ecolab Inc. (NYSE:ECL – Free Report) by 3.8% in the 3rd...
iShares MSCI USA Quality Factor ETF (BATS:QUAL) Shares Bought by Palo Alto Wealth Advisors LLC
Palo Alto Wealth Advisors LLC grew its holdings in iShares MSCI USA Quality Factor ETF (BATS:QUAL – Free Report) by...
ING Groep NV Grows Stake in HashiCorp, Inc. (NASDAQ:HCP)
ING Groep NV boosted its holdings in shares of HashiCorp, Inc. (NASDAQ:HCP – Free Report) by 851.2% in the 3rd...
Boston Omaha (NYSE:BOC) Releases Quarterly Earnings Results, Misses Estimates By $0.04 EPS
Boston Omaha (NYSE:BOC – Get Free Report) issued its quarterly earnings data on Tuesday. The company reported ($0.05) earnings per...